These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Etrolizumab in ulcerative colitis: tightening leukocyte traffic control in the inflamed mucosa. Fiorino G; Danese S Gastroenterology; 2014 Dec; 147(6):1433-5. PubMed ID: 25457851 [No Abstract] [Full Text] [Related]
4. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Warner B; Harris AW Gastroenterology; 2012 Jul; 143(1):e42; author reply e42. PubMed ID: 22634354 [No Abstract] [Full Text] [Related]
5. Successful Vedolizumab Therapy in a Sixteen-Year-Old Boy with Refractory Ulcerative Colitis. Zoet ID; de Boer NK; de Meij TG J Crohns Colitis; 2016 Mar; 10(3):373-4. PubMed ID: 26574489 [No Abstract] [Full Text] [Related]
6. Adalimumab in ulcerative colitis: ready for prime time. Danese S Dig Liver Dis; 2013 Jan; 45(1):8-13. PubMed ID: 22766323 [TBL] [Abstract][Full Text] [Related]
7. [Golimumab Therapy in Ulcerative Colitis]. Moon W Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481 [TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis. McLean LP; Cross RK Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357 [TBL] [Abstract][Full Text] [Related]
9. Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis. Kim JH; Cheon JH Gut Liver; 2016 Mar; 10(2):162-3. PubMed ID: 26934881 [No Abstract] [Full Text] [Related]
10. Vedolizumab for the treatment of ulcerative colitis. Shahidi N; Bressler B; Panaccione R Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768 [TBL] [Abstract][Full Text] [Related]
11. Vedolizumab for the treatment of ulcerative colitis. Rietdijk ST; D'Haens GR Expert Rev Clin Pharmacol; 2014 Jul; 7(4):423-30. PubMed ID: 24802046 [TBL] [Abstract][Full Text] [Related]
12. Editorial: prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Hendy P; Hart A Aliment Pharmacol Ther; 2015 Jan; 41(1):149. PubMed ID: 25483435 [No Abstract] [Full Text] [Related]
13. [Severe ipilimumab-induced ulcerative colitis remitting after infliximab therapy and secondary switching with pembrolizumab]. Yelehe-Okouma M; Granel-Brocard F; Hudziak H; Schmutz JL; Gillet P Therapie; 2018; 73(3):291-293. PubMed ID: 29203065 [No Abstract] [Full Text] [Related]
14. Clinical experience with adalimumab in anti-TNF-naïve patients with ulcerative colitis. Busquets D; Aldeguer X J Crohns Colitis; 2013 Jun; 7(5):e195. PubMed ID: 23219261 [No Abstract] [Full Text] [Related]
15. Etrolizumab for ulcerative colitis: the new kid on the block? Makker J; Hommes DW Expert Opin Biol Ther; 2016; 16(4):567-72. PubMed ID: 26914639 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis. McDermott E; Murphy S; Keegan D; O'Donoghue D; Mulcahy H; Doherty G J Crohns Colitis; 2013 Mar; 7(2):150-3. PubMed ID: 22520592 [TBL] [Abstract][Full Text] [Related]
17. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? Pouillon L; Van Stappen J; Bossuyt P; Danese S; Peyrin-Biroulet L Best Pract Res Clin Gastroenterol; 2018; 32-33():17-25. PubMed ID: 30060934 [TBL] [Abstract][Full Text] [Related]
18. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis. Tsai HH; Black C Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457 [TBL] [Abstract][Full Text] [Related]
19. Mirikizumab for the Management of Ulcerative Colitis. Venkateswaran N Gastroenterology; 2024 Apr; 166(4):710. PubMed ID: 37926125 [No Abstract] [Full Text] [Related]